In vitro suppression of k65r reverse transcriptase-mediated tenofovir- and adefovir-5′-diphosphate resistance conferred by the boranophosphonate derivatives

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 9, 2007, Pages 3162-3167

  Frangeul, Antoine ^a   Barral, Karine ^a   Alvarez, Karine ^a   Canard, Bruno ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b Centre National de la Recherche Scientifique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

9 [2 (BORANOPHOSPHONOMETHOXY)ETHYL]ADENINE DIPHOSPHATE; 9 [2 (BORANOPHOSPHONOMETHOXY)PROPYL]ADENINE DIPHOSPHATE; ADEFOVIR; ADENINE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS RESISTANCE;

ADENINE; ADENOSINE TRIPHOSPHATE; BORON COMPOUNDS; CATALYSIS; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MUTATION; PHOSPHONIC ACIDS; PLASMIDS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 35948991804     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00145-07     Document Type: Article

References (26)

1. Alvarez, K., J. Deval, B. Selmi, K. Barral, J. Boretto, C. Guerreiro, L. Mulard, S. Sarfati, and B. Canard. 2005. Borano-nucleotides: new analogues to circumvent HIV-1 RT-mediated nucleoside drug resistance. Nucleosides Nucleotides Nucleic Acids 24:419-421.
2. Arion, D., G. Borkow, Z. Gu, M. A. Wainberg, and M. A. Parniak. 1996. The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase. J. Biol. Chem. 271:19860-19864.
3. Barral, K., S. Priet, J. Sire, J. Neyts, J. Balzarini, B. Canard, and K. Alvarez. 2006. Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy) ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine. J. Med. Chem. 49: 7799-7806.
4. Bazmi, H. Z., J. L. Hammond, S. C. Cavalcanti, C. K. Chu, R. F. Schinazi, and J. W. Mellors. 2000. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)β-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 44:1783-1788.
5. Boretto, J., S. Longhi, J. M. Navarro, B. Selmi, J. Sire, and B. Canard. 2001. An integrated system to study multiply substituted human immunodeficiency virus type 1 reverse transcriptase. Anal. Biochem. 292:139-147.
6. De Clercq, E. 2001. Antiviral drugs: current state of the art. J. Clin. Virol. 22:73-89.
7. Deval, J., K. Alvarez, B. Selmi, M. Bermond, J. Boretto, C. Guerreiro, L. Mulard, and B. Canard. 2005. Mechanistic insights into the suppression of drug resistance by human immunodeficiency virus type 1 reverse transcriptase using alpha-boranophosphate nucleoside analogs. J. Biol. Chem. 280: 3838-3846.
8. Deval, J., B. Selmi, J. Boretto, M. P. Egloff, C. Guerreiro, S. Sarfati, and B. Canard. 2002. The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues. J. Biol. Chem. 277:42097-42104.
9. Deval, J., K. L. White, M. D. Miller, N. T. Parkin, J. Courcambeck, P. Halfon, B. Selmi, J. Boretto, and B. Canard. 2004. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J. Biol. Chem. 279:509-516.
10. Engel, R. 1977. Phosphonates as analogues of natural phosphates. Chem. Rev. 77:349-367.
11. Foli, A., K. M. Sogocio, B. Anderson, M. Kavlick, M. W. Saville, M. A. Wainberg, Z. Gu, J. M. Cherrington, H. Mitsuya, and R. Yarchoan. 1996. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). Antivir. Res. 32:91-98.
12. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, and M. A. Wainberg. 1994. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′- dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38:275-281.
13. Hoard, D. E., and D. G. Ott. 1965. Conversion of mono- and oligodeoxyribonucleotides to 5′-triphosphates. J. Am. Chem. Soc. 87:1785-1788.
14. Holy, A., and I. Rosenberg. 1987. Synthesis of 9-(2-phosphonylmethoxyethyl)-adenine and related compounds. Collect. Czech. Chem. Commun. 52:2801-2809.
15. Kati, W. M., K. A. Johnson, L. F. Jerva, and K. S. Anderson. 1992. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 267: 25988-25997.
16. Lewis, D. A., K. Bebenek, W. A. Beard, S. H. Wilson, and T. A. Kunkel. 1999. Uniquely altered DNA replication fidelity conferred by an amino acid change in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 274:32924-32930.
17. Margot, N. A., E. Isaacson, I. McGowan, A. K. Cheng, R. T. Schooley, and M. D. Miller. 2002. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 16:1227-1235.
18. Meyer, P., B. Schneider, S. Sarfati, D. Deville-Bonne, C. Guerreiro, J. Boretto, J. Janin, M. Veron, and B. Canard. 2000. Structural basis for activation of alpha-boranophosphate nucleotide analogues targeting drug-resistant reverse transcriptase. EMBO J. 19:3520-3529.
19. Robbins, B. L., R. V. Srinivas, C. Kim, N. Bischofberger, and A. Fridland. 1998. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob. Agents Chemother. 42:612-617.
20. Sarafianos, S. G., V. N. Pandey, N. Kaushik, and M. J. Modak. 1995. Site-directed mutagenesis of arginine 72 of HIV-1 reverse transcriptase. Catalytic role and inhibitor sensitivity. J. Biol. Chem. 270:19729-19735.
21. Selmi, B., J. Boretto, S. R. Sarfati, C. Guerreiro, and B. Canard. 2001. Mechanism-based suppression of dideoxynucleotide resistance by K65R human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue. J. Biol. Chem. 276:48466-48472.
22. Sluis-Cremer, N., D. Arion, N. Kaushik, H. Lim, and M. A. Parniak. 2000. Mutational analysis of Lys65 of HIV-1 reverse transcriptase. Biochem. J. 348:77-82.
23. Tisdale, M., T. Alnadaf, and D. Cousens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41:1094-1098.
24. Tuske, S., S. G. Sarafianos, A. D. Clark, Jr., J. Ding, L. K. Naeger, K. L. White, M. D. Miller, C. S. Gibbs, P. L. Boyer, P. Clark, G. Wang, B. L. Gaffney, R. A. Jones, D. M. Jerina, S. H. Hughes, and E. Arnold. 2004. Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat. Struct. Mol. Biol. 11:469-474.
25. Wainberg, M. A., M. D. Miller, Y. Quan, H. Salomon, A. S. Mulato, P. D. Lamy, N. A. Margot, K. E. Anton, and J. M. Cherrington. 1999. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir. Ther. 4:87-94.
26. White, K. L., N. A. Margot, T. Wrin, C. J. Petropoulos, M. D. Miller, and L. K. Naeger. 2002. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. 46:3437-3446.